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Abstract
Colorectal cancer will kill approximately 50,000 people in the United States
this year (ACS, 2008). Current treatment options, including surgery, chemo-
therapy, and radiation, are often able to force the cancer into remission, but
better treatments are needed to help those who don’t respond to current
treatments. A new and promising treatment option, monoclonal-antibody
therapy, has the potential to help reduce the deaths caused by colorec-
tal cancer, but most monoclonal-antibody drugs are currently still in trial
phases, and the variations in the dosing schedule of those currently ap-
proved for use have not been heavily explored. We have modified a non-
linear ODE tumor/treatment model by de Pillis and colleagues (2009) to in-
clude monoclonal antibody treatments. Parameter values have been mod-
ified for colorectal cancer, with irinotecan as the chemotherapy agent and
the two monoclonal antibodies cetuximab, which is FDA approved, and
panitumumab, which is still undergoing clinical trials. We have run Mat-
lab simulations of current treatment options, and have found new dosing
schedules which, in our simulations, reduce tumor size more effectively
that the current schedules. Equilibria of the system and its sensitivity to
parameters have also been examined.
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Chapter 1
Introduction
Cancer is one of the leading causes of death in the United States, behind
only heart disease (ACS, 2008). According to the American Cancer So-
ciety, colorectal cancer accounts for approximately 10 percent of cancer
cases in the United States, and approximately 9 percent of cancer-related
deaths (ACS, 2008). Colorectal cancer is mainly a disease of the elderly,
with a median age at diagnosis of 71 years (Goldberg and Carrato, 2008).
Although colorectal cancer incidence rates have declined over the last 10
years, it is still a significant cause of death in the United States (ACS, 2008).
A new treatment option, the use of monoclonal antibody drugs, has re-
cently been explored as a possible approach to controlling colorectal can-
cer, but there are still many unanswered questions about the effectiveness
of monoclonal antibodies and how they should be used. The goal of this
work is to contribute to the understanding of how best to use monoclonal
antibodies in the treatment of colorectal cancer. We have built a system of
nonlinear ordinary differential equations (ODEs) that model the growth of
a colorectal tumor and its interactions with the host’s immune system. Us-
ing this model, we consider three different types of treatment. We will then
run simulations and examine possible treatment regimens.
Chapter 2 gives an overview of the anatomy of the colon and rectum,
the relevant features of the immune system, the growth of a colorectal
tumor, and some of the current treatment options. Chapter 3 gives an
overview of the previous work done to mathematically model colorectal
tumors and treatments. Chapter 4 describes the system of equations, and
Chapter 5 describes the parameters used in the equations. Chapter 6 pre-
sents our results and analysis of the model, and Chapter 7 is a discussion
of the significance of our results and possible future directions.

Chapter 2
Biology Background
To understand why the terms in our equations have been added and how
the parameters have been derived, it is first necessary to understand how
the human immune system functions and how it interacts with a growing
tumor.
2.1 The Healthy Colon
The colon and rectum are found at the end of our gastrointestinal tract,
which is responsible for digesting food and absorbing nutrients. The sur-
face of our colon is covered by a single layer of epithelial cells and is lined
with small pits called “crypts” (Sompayrac, 2004). The cells in our colon
and rectum have a lifetime of less than one week, and so are continu-
ally replaced by the proliferation of stem cells that can reproduce indefi-
nitely (Sompayrac, 2004). These stem cells are found at the bottom of the
crypts, and as they create new epithelial cells, the old cells are pushed to the
surface and removed (Figure 2.1(a)) (Sompayrac, 2004). In a healthy colon,
stem-cell proliferation is carefully controlled, and just enough new epithe-
lial cells are produced to replace those that have died (Sompayrac, 2004).
However, if mutations occur in the growth-control system of an epithelial
cell, this careful control can be lost, and a tumor is formed (Figure 2.1(b)).
2.2 Overview of the Immune System
This section will briefly explain the role of the cells and protein messengers
in the immune system relevant to this model for colorectal cancer. It will
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(a) Normal crypt. (b) Cancerous crypt.
Figure 2.1: A normal crypt in the colon, and a crypt that has developed
mutations and become cancerous (Reya and Clevers, 2005).
look at two parts of the immune system: the innate immune system, which
responds quickly to invaders, but with a nonspecific and less effective re-
sponse, and the adaptive immune system, which responds more slowly but
is targeted at a specific invader. Information on other parts of the immune
system, as well as a summary of the parts of the immune system discussed
here, can be found in Appendix A. Unless otherwise noted, this informa-
tion is from Lauren Sompayrac’s How the Immune System Works (2008).
2.2.1 Innate Immune System
The innate immune system responds to invaders as soon as they enter
the body. It uses three main response pathways: the complement system,
professional phagocytes, and natural killer cells. The complement system is
composed of about 20 proteins that, when activated, can destroy invaders
through a process called complement-dependent cytotoxicity (CDC). The com-
plement system can be activated in multiple ways, one of which is activa-
tion by antibodies, which we will explain as part of our discussion of the
adaptive immune system in Section 2.2.2.
When blood cells mature, they can become either hemoglobin-carrying
”red” blood cells, or they can become the cells of our immune system, the
non hemoglobin-carrying ”white” blood cells, or leukocytes(Figure 2.2). The
professional phagocytes are made up of two different kinds of leukocytes,
and are responsible for engulfing invaders and destroying them.
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Figure 2.2: Types of blood cells (Dharmananda, 2005).
Natural Killer Cells
Natural killer cells (NK cells), another type of leukocyte, have multiple jobs.
When they receive chemical signals called cytokines from other members
of the innate immune system, they are responsible for producing more of
these signals and passing them on to other cells. NK cells are also respon-
sible for examining the proteins present on a cell and deciding whether or
not that cell belongs to the host. NK cells look for a protein called MHC
I, which displays short peptide sequences called antigens from the proteins
contained in the cell. Most of our cells have many copies of MHC I on their
surface, and these proteins inhibit NK cells. So, if an NK cell find a cell that
does not display many MHC I proteins, it can induce apoptosis, causing
the cell to commit suicide. However, NK cells need to be activated before
they can search for invading cells. One way that they can be activated is
with interleukin-2 (IL-2), a type of cytokine. Another method of NK cell
activation relying on antibodies, called antibody-dependent cellular cytotox-
icity (ADCC), will be explained as part of the discussion of the adaptive
immune system in Section 2.2.2.
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2.2.2 Adaptive Immune System
Once the innate immune system has been activated, the adaptive immune
system begins making antibodies for the current invader. These antibod-
ies are pieces of proteins which match the invader’s, but not the host’s,
proteins, and tell leukocytes which cells to destroy. Antibodies have many
jobs, including guiding macrophages and activating the complement cas-
cade, but lymphocyte activation is their most important job. Lymphocytes,
a type of leukocyte, are programmed to find invaders matching their anti-
bodies, and to effectively kill them. Killer T-cells and NK cells are the two
types of lymphocytes we will look at specifically in this model.
Killer T-Cells
Killer T-cells (or cytotoxic T cells, CTLs), part of the adaptive immune sys-
tem, are responsible for finding invaders once the invaders have already
entered a cell. Each CTL contains receptors which bind to a specific antigen
that the body has already verified belongs to an invader. Once a CTL has
been activated, the CTL’s receptors search for a cell with its specific anti-
gen. When the CTL finds its antigen, a protein on the surface of the CTL,
called CD8+, binds to the antigen, an MHC I protein on the invader, and in-
duces apoptosis. However, before a CTL can find invaders, it must wait for
the innate immune system to detect invaders and send out interleukin-2,
which activates the CTLs.
Natural Killer Cells and the Adaptive Immune System
NK cells can also interact with certain types of antibodies. Antibodies are
small proteins that bind to foreign peptide sequences displayed by MHC I
proteins, and, by also binding to other cells in our immune system, create a
link between the two and allow for more effective killing. Some antibodies,
specifically certain subclasses of the IgG antibodies, are able to bind to NK
cells, making the NK cells more cytotoxic (more effective killers). These
antibodies simultaneously activate the NK cells and direct them to their
target. This process is called “antibody-dependent cellular cytotoxicity”
(ADCC).
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2.3 Colon Cancer and Treatments
Normal cells undergo carefully regulated cell division (proliferation). How-
ever, cells are mutated, this carefully controlled regulation can be lost. This
section will describe what happens when colon cells proliferate, and how
this problem can be treated. Unless otherwise noted, this information is
from Lauren Sompayrac’s How Cancer Works (2004).
2.3.1 Colon Cancer
When mutations occur, the normal control systems of cells can be damaged
or lost. Mutations affecting the growth control systems happen frequently
in the epithelial cells of the colon as we age, causing “fingers” of cells called
polyps to grow out from the colon wall. New blood vessels develop within
these polyps, allowing the cells to extend further outward. Polyps can be
removed fairly easily and examined to see what mutations the cells have
undergone. Most mutations that result in polyp formation only give the
cell a small proliferation advantage, and these polyps are considered be-
nign. However, approximately 1 percent of these polyps will become can-
cerous, and will have unregulated proliferation. Many will also have other
mutations that destroy the cells’ ability to divide correctly and check for
errors during cell division, resulting in even more mutations. The cells
from these cancerous polyps will break off into the blood stream, and then
reattach themselves at another location in the body and begin proliferating
again. When this happens, the tumor is said to have metastasized, and can
no longer be removed by surgery alone.
2.3.2 Current Treatments
Surgery is often an effective treatment option for colorectal cancer. How-
ever, if the tumor has metastasized, or if the oncologist wants to ensure that
all of the cancerous cells have been removed, other treatment options may
also be used.
Chemotherapy
Chemotherapy involves the administration of chemicals into the blood that
target cell division. Thus the cells in the body that normally have a high
turnover rate (such as any cancerous cells present) are no longer able to
reproduce. Chemotherapy drugs are now being used in conjunction with
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other medications aimed at strengthening the response of the immune sys-
tem (Gravalos et al., 2009; Siena et al., 2009; Martinelli et al., 2009; De Vita,
Jr et al., 2000).
Immunotherapy
Many cells in our body rely on epidermal growth factor (EGF) to help them
decide when to proliferate. The binding of EGF to an epidermal growth-
factor receptor (EGFR) triggers a signaling cascade in the cell that results
in cell proliferation (Martinelli et al., 2009). Many tumors have a mutation
that upregulates, or increases, the number of epithelial growth factor recep-
tors (Gravalos et al., 2009; Siena et al., 2009; Martinelli et al., 2009; De Vita,
Jr et al., 2000). Because so many cancerous cells have this mutation, these
EGFRs have recently become the target of a new cancer treatment, mono-
clonal antibodies.
Monoclonal antibodies (MABs) are small antibodies that are manufac-
tured to bind to specific proteins. Some monoclonal antibodies compete
with EGF to bind to the extracellular domain of EGFR, the part of the recep-
tor that protrudes from the cell, waiting for an EGF to bind. Monoclonal
antibodies have a much higher affinity for EGFR than EGF does, and thus
they are able to prevent EGFs from binding to EGFR and the proliferation
signaling cascade from starting (Martinelli et al., 2009). When the cells with
high numbers of EGFRs can no longer proliferate as quickly, the immune
system has a better chance of killing them before they can multiply further.
Cetuximab and panitumumab, both monoclonal antibodies that target
EGFR, are promising new treatments for colorectal cancer. Cetuximab,
used with or without the chemotherapy medication irinotecan, has been
shown to improve survival times and quality of life (Martinelli et al., 2009).
Cetuximab is an IgG1 antibody, a subclass that is able to elicit ADCC from
NK cells, thus increasing the NK cells’ cytotoxicity (Martinelli et al., 2009).
Panitumumab is a newer drug and has undergone fewer clinical trials. Pan-
itumumab has been shown to decrease tumor growth rate, but the clinical
trials have not yet been able to confirm that it increases overall survival
time (Martinelli et al., 2009). Both cetuximab and panitumumab are able to
activate the complement cascade of the innate immune system (De Vita, Jr
et al., 2000). Both are also able to increase chemotherapy’s toxicity to tumor
cells, because the tumor cells are killed more easily and cannot replace their
population as quickly when they are unable to reproduce (De Vita, Jr et al.,
2000).
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Currently, monoclonal-antibody treatments are very new and are mainly
used in patients with metastatic cancer, particularly when no other treat-
ment has worked (Martinelli et al., 2009). However, it is possible that with
the positive results from current clinical trials, monoclonal antibodies may
become a more significant part of colorectal-cancer treatment.

Chapter 3
Prior Mathematical Work
Many previous tumor models have been created, although very few look
specifically at colorectal cancer, and none have been found in our research
that model monoclonal antibodies. We will briefly present the models cre-
ated by de Pillis and colleagues (2009; 2008; 2005), on which this work is
based, and will then examine others models which may be a useful com-
parison and reference for our work.
3.1 ODE Tumor Models
Much of the work previously done on cancer modeling, particularly for
colon cancer, has examined spatial growth, and so builds a system of par-
tial differential equations (PDEs). We will be using ordinary differential
equations (ODEs) in our model, and so will focus our description of previ-
ous work on models using ODE systems.
3.1.1 Previous Versions of Our Model
The model presented here is developed from the work of de Pillis and
colleagues, in which tumor-cell population, immune-cell populations, and
drug concentrations are modeled with a series of nonlinear ODEs. This
model also includes patient-specific parameters representing the strength
of the patient’s immune system. This model has been validated with pub-
lished studies on mice and humans (de Pillis et al., 2005). It has successfully
demonstrated the need for immunotherapy in addition to chemotherapy to
prevent the tumor from growing again after drug therapies have been com-
pleted, and has studied the importance of the patient-specific parameters in
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the effectiveness of immunotherapy treatment (de Pillis et al., 2009, 2008).
This work adapts the model of de Pillis and colleagues to include terms for
monoclonal-antibody treatment and adjusts the parameters to fit specifi-
cally with colorectal cancer.
3.1.2 Other ODE Models
Simpler ODE models have also been developed to describe the develop-
ment of tumors (Gatenby and Vincent, 2003; Kuznetsov et al., 1994). These
models are both used mainly to examine equilibrium points. Gatenby and
Vincent (2003) track populations of tumor cells and normal cells. They
show that with only chemotherapy, there is an unstable equilibrium point
when the tumor cell population is zero, and a stable equilibrium point
when the tumor cell population reaches the carrying capacity of the tis-
sue. They concluded that with only chemotherapy, the growth rate of the
tumor-cell population is always positive as long as the tumor-population
is positive. Thus, according to Gatenby and Vincent’s model, chemother-
apy alone will not be enough to prevent the tumor from rebounding. This
agrees with the conclusions of de Pillis and colleagues (2008).
Kuznetsov’s team (1994) tracks populations of cytotoxic cells and tu-
mor cells. Their model shows a theoretical value where the host’s immune
system will be able to keep the tumor-cell population under control indefi-
nitely. However, Kuznetsov and colleagues acknowledge that as time pro-
gresses, some change will occur (e.g. a change in immune-system param-
eters or a new mutation in the tumor cells) that will cause tumor growth
to cross the bifurcation border. They found that one of the most critical
parameters was a value representing the rate at which cytotoxic cells were
inactivated due to interactions with the tumor (Kuznetsov et al., 1994).
3.2 PDE Tumor Models
Ordinary differential equations are, computationally, much easier to work
with than partial differential equations. However, the use of ODEs in this
work requires the simplifying assumption of a cell count to represent a
three-dimensional tumor, and assumes that every cell is identical, regard-
less of its location in the tumor. Thus it is important to verify that this
simplification does not adversely affect the accuracy of the model. For this,
we find the work of Johnston and colleagues (2007) to be useful.
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Johnston’s team (2007) consider two different approaches to the mod-
eling of cells in a colonic crypt. They first consider a compartmental ap-
proach, which tracks the locations and ages of stem cells; transit cells, which
move up the wall of the crypt to the surface; and differentiated cells. Each
of these populations, located in different parts of the colonic crypt, has dif-
ferent characteristics. As the cells mature they move through the different
compartments, corresponding to a physical movement of the crypt walls
towards the surface of the colon. In this model, Johnston’s team sets a dif-
ferent cell-cycle length for each of the cell populations, so that the cells can
divide and mature further at different rates, depending on where they are
located in the crypt. With this first model, they tracked the cell cycles of
each cell, which provided information on how quickly the cell was moving
between compartments, and thus could be used to find an overall growth
rate.
However, this approach resulted in equations which were very difficult
to work with. So, the authors also developed a continuous approximation
for their equations by integrating over all cell ages. The resulting ODE
system still considers the cell populations to be separate, but movement
between cell populations is just considered to be a rate instead of taking
into account the discrete movement of cells resulting from different cell
cycle lengths. They found that this continuous model provided a good
approximation for the growth rate found by the age-differentiated model,
for a sufficiently large time scale.

Chapter 4
Equations
In this update of the model presented by de Pillis and colleagues (2009),
we will include a new treatment option, monoclonal antibodies, and will
remove the interleukin treatment option. IL-2 treatments are not effective
against colorectal cancer (Rosenberg, 1988), and thus are not used here.
We will also modify parameters to be specific to colorectal cancer and the
chemotherapy medication irinotecan, and will find parameters for the mon-
oclonal antibodies cetuximab and panitumumab.
A new state variable A, representing monoclonal-antibody concentra-
tion, has been created, and terms have been added to the model to include
the actions of monoclonal antibodies on other types of cells in the body. We
define our state variables as follows:
• Cell Populations
T(t) the total tumor cell population;
N(t) the concentration of NK cells per liter of blood (cells/L);
L(t) the concentration of CD8+T cells per liter of blood (cells/L);
C(t) the concentration of lymphocytes per liter of blood, not includ-
ing NK cells and active CD8+T cells (cells/L).
• Concentrations
M(t) the concentration of chemotherapy per liter of blood (mg/L);
I(t) the concentration of interleukin per liter of blood (IU/liter);
A(t) the concentration of monoclonal antibodies per liter of blood
(mg/liter);
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• Treatments:
vL(t) the number of tumor-activated CD8+T cells injected per day
per liter of blood (cells/liter per day);
vM(t) the amount of irinotecan injected per day per liter of blood
(mg/liter per day);
vA(t) the amount of monoclonal antibodies injected per day per liter
of blood (mg/liter per day).
4.1 System of Equations
New terms and a new equation have been added to the ODE system given
in the model by de Pillis and colleagues (2009). A summary of the purpose
for each term can be found in Appendix B.1. The new ODEs of the model
are given below, with changes shown in bold:
dT
dt
= aT(1− bT)− (c+ ξ A
h1 + A
)NT − DT
− (KT + KATA)(1− e−δTM)T −ψAT (4.1)
dN
dt
= f (
e
f
C− N)− (p+ pA Ah1 + A )NT +
pNNI
gN + I
− KN(1− e−δNM)N (4.2)
dL
dt
=
θmL
θ + I
+ j
T
k+ T
L− qLT + (r1N + r2C)T − uL
2CI
κ + I
− KL(1− e−δLM)L+ pILIgI + I + vL(t) (4.3)
dC
dt
= β(
α
β
− C)− KC(1− e−δCM)C (4.4)
dM
dt
= − γM+ vM(t) (4.5)
dI
dt
= − µI I + φC+ ωLI
ζ + I
(4.6)
dA
dt
= − ηA−λT A
h2 + A
+ vA(t) (4.7)
where
D = d
(L/T)l
s+ (L/T)l
. (4.8)
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Figure 4.1: Possible pathways for MAB-induced tumor death.
4.2 Justifications of New Terms
The justification of all unchanged terms can be found in the 2009 paper by
de Pillis and colleagues.
In Equation 4.1, three new terms have been added to represent the
three pathways of MAB-induced tumor-cell death (see Figure 4.1). The
term −ξ Ah1+ANT represents the rate of tumor-cell death caused by ADCC
(see Section 2.2.2). Some monoclonal antibodies have protein structures
which, when bound to a tumor cell, allow them to simultaneously activate
NK cells and direct them to the invader (De Vita, Jr et al., 2000). Thus,
when a MAB/tumor-cell complex and NK cell meet, the tumor cell is more
likely to be killed than when an NK cell meets an unbound tumor cell.
Kurai and colleagues (2007) found that cetuximab has a threshold con-
centration above which ADCC activity no longer increases. So, we as-
sume that ADCC activity will increase with MAB concentration until it
becomes saturated, and we model this with a sigmoid function. The term
−KATA(1 − e−δTM)T represents the rate of chemotherapy-induced death
of tumor cells, assisted by monoclonal antibodies. When tumor cells are
not able to proliferate, they are much more susceptible to chemotherapy-
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induced death (De Vita, Jr et al., 2000). So, when MABs are bound to tu-
mor cells, blocking their EGFRs and thus inhibiting tumor cell prolifera-
tion, they will increase the tumor-cell death caused by chemotherapy. The
term−ψAT will account for the rate of tumor-cell death caused by tumor
cell interactions with only MABs. This term will include tumor-cell death
from CDC (see Sections 2.2.1 and 2.3.2), from a reduction in EGF binding,
and thus tumor-growth rate (De Vita, Jr et al., 2000), and from any other
pathway currently unknown.
In Equation 4.2, one new term has been added. The term −pA Ah1+ANT
represents the rate of NK-cell death due to ADCC interactions with tumor
cells and monoclonal antibodies. We assume that ADCC activity increases
with MAB concentration until it becomes saturated. As with the term
−pNT, it is assumed that NK cells will experience exhaustion of tumor-
killing resources after interactions with tumor cells (Bhat and Watzl, 2007).
No changes were made in Equations 4.3, 4.4, and 4.5. It is worth not-
ing, however, that we considered an additional term representing MAB-
induced lymphocyte (including NK-cell and CD8+T-cell) death. Many cells,
including some cells in the immune system, express EGFR. While it seems
likely that the MABs would also bind to EGFRs on non tumor cells, the
literature suggests that the effect of MABs is specific to tumor cells (Ro-
driguez et al., 2009; Martinelli et al., 2009; Gravalos et al., 2009; Siena et al.,
2009; De Vita, Jr et al., 2000). Also, the usual symptoms associated with
the death of quickly proliferating host cells, including hair loss and dam-
age to the gastrointestinal tract, have not been reported as side effects of
MAB treatments (De Vita, Jr et al., 2000; Martinelli et al., 2009; Gravalos
et al., 2009). Tumors in colorectal cancer often overexpress only one of four
growth-factor receptors, HER-1, which is the growth factor that MABs tar-
get (Gravalos et al., 2009). It is possible that the MABs affect other EGFR-
presenting cells, but that blocking EGFRs on normal cells does not have a
large enough effect to be detectable. Also, the majority of a MAB’s path-
ways result in either activation of the immune system (such as ADCC or
CDC) or a decrease in growth rate, and do not result directly in cell death.
This may contribute to the specificity of MAB effects to tumor cells.
The only change made to Equation 4.6 was the deletion of the term
vI(t), representing exogenous IL-2 treatment (de Pillis et al., 2009). The
injection of additional cytokines has been shown to not be an effective treat-
ment for colorectal cancer, and so does not need to be included. However
the remainder of the terms were left, as endogenous interleukin is pro-
duced naturally in the body and is important in activating NK cells and
CD8+T cells against (Eckert et al., 1997).
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Finally, Equation 4.7 has been added to handle the model’s new treat-
ment option, injections of monoclonal antibodies. The term vA(t) repre-
sents MAB treatments. Because MABs are not produced naturally in the
body, no additional growth terms are needed. The term −ηA represents
the natural degradation of the MAB protein in the body. The term−λT Ah2+A
represents the loss of available MABs as they bind to tumor cells. During
the chemotherapy-induced and NK-cell-induced deaths of tumor cells in
MAB/tumor-cell complexes, MAB/tumor-cell binding is the first step in
the process (De Vita, Jr et al., 2000), so all MABs bound to tumor cells can
be included in this term, whether they are participating in ADCC, CDC,
growth rate reduction, chemotherapy-induced death, or another mecha-
nism. Because MABs have a very strong binding affinity for their target
growth-factor receptors, and because there are many growth factor recep-
tors on every cell, we assume that many MABs will be lost with each tumor
cell. Also, we assume that the growth factor receptors will be fully satu-
rated when the MAB concentration is significantly higher than the growth
factor receptors. That is, we can approximate the number of MABs lost
with each tumor cell as the number of growth-factor receptors on that cell,
as long as MAB concentration is above a critical value to be determined in
Section 5.8. To incorporate this threshold concentration, we added a satu-
ration term similar to the one found in Equation 4.1.

Chapter 5
Parameters
In order to determine parameter values, we searched peer-reviewed liter-
ature for in vitro and in vivo studies of colorectal tumor growth that could
provide data for the following cases: no treatment, with irinotecan chemo-
therapy treatment, with cetuximab MAB treatment, and with panitumumab
MAB treatment. Some of the parameters used here are those found by
de Pillis and colleagues (2009) and their derivation will not be repeated
here. The description of each parameter can be found in Appendix B.2 and
a summary of the values used for each parameter can be found in Appen-
dix B.3.
5.1 Initial Conditions
Initial conditions are determined for both a healthy individual and for the
patients we will be considering, who have previously undergone treatment
for their tumors. The initial values of N, L, C, and I can be determined for
each of these patients by considering biological arguments for reasonable
cell concentrations of patients with a strong and weak immune system. We
assume that the healthy individual is in homeostasis, meaning that the cell
populations will remain constant. This allows us to use the initial condi-
tions of the healthy patient to determine where the stable equilibria in our
system should be. We will then be able to plot these initial values with our
system of equations to ensure that we have the desired stable equilibrium
states, reflecting the realistic biological values.
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(a) The no tumor equilibrium, for a patient
with a health immune system, not receiv-
ing any treatment.
(b) The large tumor equilibrium, for a pa-
tient with a health immune system, not
receiving any treatment.
Figure 5.1: Stable equilibria of the system.
5.1.1 No Tumor Equilibrium with a Strong Immune System
We first calculated initial conditions for a healthy patient with no tumor
(T = 0) and receiving no cancer treatments (M = A = 0) to find a no
tumor equilibrium. Because we are assuming that the healthy patients are
in homeostasis, we can set each time derivative equal to zero. We found N
and C by assuming a lymphocyte count of 3.333× 109 cells, which is within
the range for a normal lymphocyte count, and assuming natural killer and
CD8+ T cell counts to be 10 percent and < 1 percent, respectively (Abbas
and Lichtman, 2005). This gives us that C = 3.333× 109 × 0.9 = 3× 109
and N = 3.333× 109 × 0.1 = 3.333× 108. The values for L and I are taken
from de Pillis’s team (2009), who derives L from Pittet’s team 1999 and
Speiser’s team (2001), and I from Orditura’s team (2000) and information
provided by Novartis Pharmaceuticals (2007). These calculations give us
the following values for our no tumor equilibrium:
T = 0, N = 3.333× 108, L = 2.526× 104, C = 3× 109, M = 0,
I = 48.9273, A = 0.
After parameter values were found, we were able to show graphically that
these initial conditions appear to correspond to a stable equilibrium state
of the system (see Figure 5.1(a)).
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5.1.2 Large Tumor Equilibrium with a Strong Immune System
We next calculated initial conditions for a healthy individual who has a
large tumor but is not receiving any treatment (M = A = 0). We again
set the time derivatives to zero under the assumption of homeostasis. Un-
der conditions of an untreated tumor, we leave N and C at the same val-
ues, but use larger values for I and L, since the presence of a tumor in-
creases the production of cytokines. We take the values of I = 1173 and
L = 5.268× 105 from de Pillis and colleagues (2009), who derive L from
Lee’s team (1999) and Janeway’s book on Immunobiology (2005), and I again
from Orditura’s team (2000) and information provided by Novartis Phar-
maceuticals (2007). With these initial values and the parameters that can be
directly calculated from available literature, we solve for the size of a large
tumor in equilibrium while solving for the parameter p in Section 5.3. Note
that the resulting value, T = 4.65928× 109, is slightly less than the theo-
retical carrying capacity of 4.66× 109 which we find during the calculation
of the parameter b in Section 5.2. This is expected, because interactions
with the immune system prevent the tumor from reaching its theoretical
carrying capacity. These initial values give us the following large tumor
equilibrium:
T = 4.65928× 109, N = 3.333× 108, L = 5.268× 105, C = 3× 109,
M = 0, I = 1173, A = 0.
We were again able to show graphically that these initial conditions appear
to correspond to a stable equilibrium state of the system (see Figure 5.1(b)).
5.1.3 Initial Conditions for a Weakened Immune System
Because the majority of the patients we were considering had previously
undergone various treatments and did not have very strong immune sys-
tems, we reduced the initial values for N, L, and C in our simulations. We
used an initial value of C = 109 for the lymphocyte population. This value
is within the normal range for lymphocyte concentration, but is very close
to being low (Abbas and Lichtman, 2005). We considered N and L to be a
slightly lower percentage of total lymphocytes than in a healthy individual,
and set N = 9× 107 and L = 5× 104. These two populations, the natural
killer cells and activated CD8+T cells, interact more directly with the tu-
mor than the other lymphocytes, so we assume that they are deactivated at
a slightly higher rate. Initial values for M and A are set to zero, but dMdt and
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(a) T(0) = 1.1× 107 cells. A tumor with
a small initial size will quickly shrink to
zero.
(b) T(0) = 1.4× 107 cells. A tumor with
a large initial size will quickly grow to
the carrying capacity of the system.
Figure 5.2: Patients who begin at our initial conditions can end up at either
the no tumor equilibrium or the large tumor equilibrium.
dA
dt will be nonzero at any time t when the patient is receiving treatments.
Because the presence of tumors fragments stimulate IL-2 production (Som-
payrac, 2008), we leave I = 1173 as the initial value for I. The initial value
of T can be varied, and will be stated with simulations. These calculations
give us the following initial conditions for the other populations in our
model:
N(0) = 9× 107, L(0) = 5× 104, C(0) = 109, M(0) = 0,
I(0) = 1173, A(0) = 0.
These initial values represent patients who are not in homeostasis, and de-
pending on the initial tumor size, the strength of interactions between the
patient’s immune system and the tumor, and whether any medication is
given, their cell populations can be driven either to the no tumor equilibrium
or to the large tumor equilibrium. Sample conditions for a tumor that is re-
duced to the no tumor equilibrium can be seen in Figure 5.2(a), and sample
conditions for a tumor that grows to the large tumor equilibrium can be seen
in Figure 5.2(b).
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5.2 dTdt : The Tumor
a = 2.31 × 10−1 day−1, the tumor growth rate, was calculated from the
doubling time of colorectal tumors during exponential growth, which
was found by Corbett’s team (1975) to be 3 days. We can calculate a
from the equation for exponential growth with a half-life of t = 3
days. So, 2t0 = t0eat, giving us that a =
ln(2)
3 = 2.31× 10−1. This is
approximately half of the value for a found by de Pillis’s team (2009),
but colon tumors are known to have slower growth rates than most
types of cancer, so this is not an unreasonable value (Bolin et al., 1983;
Burnett and Greenbaum, 1981). It is important to note that Corbett’s
team grew their tumors in non immunodeficient mice. However this,
was the only study in our literature search that provides the dou-
bling time specifically during exponential growth. The growth rate
that we calculated is comparable to the value found by de Pillis and
colleagues (2009), and also agrees with the initial growth rates found
by Leith’s team (1987), who grew colon tumors in immunodeficient
mice.
b = 2.146× 10−10 cells−1, is the inverse of the carrying capacity. The carry-
ing capacity (in volume) of colorectal tumors was taken from Leith
and colleagues (1987), who collected tumor growth data, fit them
to the Gompertz equation, and found the maximum tumor size as
t → ∞. The carrying capacity derived from the Gompertz model has
the same biological interpretation as in our model, so we were able to
use the results of Leith’s team to find a value for b. Multiple carrying
capacities were found from different colorectal tumor lines, with an
average of approximately 10,000 mm3 = 1013 µm3. This size was then
converted to a cell population using 2145 µm3 as the average tumor
cell volume (Chen et al., 2005), giving 1013µm3/(2145µm3/cell)=4.66×
109 cells. Thus, b = (4.66× 109 cells)−1 = 2.146× 10−10.
c = 5.156× 10−14 L cells−1day−1, the rate of NK-induced tumor death, is
set equal to p (see Section 5.3) as was done by de Pillis’s team de Pil-
lis et al. (2009). Recent research (Bhat and Watzl, 2007) suggests that
natural killer cells may be able to kill up to six tumors before deacti-
vation. However we have not found further confirmation of this and
so have chosen to continue using the assumption that NK cells are
only able to kill one tumor cell each.
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D = d (L/T)
l
s+(L/T)l involves three parameters, to which we assign four sepa-
rate values each, in order to reflect a variety of patient-specific states.
These parameters are: d (day−1), the immune-system strength coef-
ficient; l, the immune-system strength scaling coefficient; and s (L),
the value of ( LT )
l necessary for half-maximal CD8+ T-cell toxicity. We
base our values for d, l, and s on the values used by de Pillis and
colleagues (2009), however we slightly lower d and l and slightly
raise s to represent that many of our patients are not in very good
health and have gone through multiple cancer treatments. We use
d ∈ {1.3, 1.6, 1.9, 2.1}, l ∈ {1.1, 1.4, 1.7, 2.0}, and s ∈ {4× 10−3, 7×
10−3, 9 × 10−3, 3 × 10−2}, which results in sixty-four different “pa-
tients” over which we can run simulations to represent clinical trials.
ξ = 6.5× 10−10 L cells−1day−1 for cetuximab, and = 0 for panitumumab,
is the rate of NK-induced tumor death through ADCC. The value for
cetuximab was set to match the expected increase in NK cell activity
found by Kurai and colleagues (2007). Kurai’s team varied concen-
trations of tumor cells and NK cells, left them for 4 hours with and
without 0.25µg/mL cetuximab, and measured the resulting NK ac-
tivity. They measured the activity at much higher concentrations of
NK cells than are present in the body, but based on their results we
approximated that at the ratio of one NK cell: ten tumor cells, NK ac-
tivity is increased by 10 percent. We found an appropriate value for ξ
by running simulations up to t = 4 hours, T0 = 109, N0 = 2.5× 108,
and an initial treatment of 0.25 mg/L cetuximab over 15 minutes. The
other immune system components, as well as natural growth and de-
cay, were ignored. A value of ξ = 6.5× 10−10 was found to give the
desired 10 percent decrease in NK cells, which we use as a proxy for
an increase in NK activity of 10 percent. Panitumumab is unable to
activate the ADCC pathway, so ξ is set to zero in that case (Grothey,
2006).
h1 = 1.25× 10−6 mg L−1 for cetuximab, and 0 for panitumumab, is the con-
centration of MABs necessary for a half-maximal increase in ADCC.
The ADCC activity level indicated by ξ is reached when the cetux-
imab concentration is above 0.25µg/mL, and so h1 was set to .5 ×
0.25µg/mL= 1.25 × 10−6 mg/L. Cetuximab levels in the body are
usually above this threshold during treatment (at about one fiftieth
of a normal dose), and we chose to use a sigmoid function to cap-
ture this threshold. Although we do not have evidence supporting
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Figure 5.3: The probability density function of x and y.
that ADCC activity increases according to a saturation function, this
model captures the two important characteristics: that the threshold
concentration for maximal ADCC activity is much lower than the nor-
mal cetuximab dose, and that the ADCC activity level approaches
zero as MAB concentration approaches zero. We chose h1 so that,
when the cetuximab concentration is half of the threshold value, the
term Ah1+A will be one half, resulting in half-maximal ADCC activity.
Because panitumumab does not play a role in ADCC, panitumumab
does not have an h1.
KT = (8.1× 10−1)x day−1 is the rate of chemotherapy-induced tumor death,
where x is a random variable with the probability density function (the
likelihood of x taking on each value) shown in Figure 5.3. We chose
this random variable because we wanted x ∈ [0, 1]. Also, we wanted
x to be close to one most of the time, and this random variable has an
expected value (mean value) of E[x] = 0.75. Therefore, KT ∈ [0, 8.1×
10−1], and has a mean value of KT = 6.075× 10−1. Multiplying the
maximum value for KT by this random variable allows us to represent
that each tumor is affected differently by chemotherapy medications.
Each patient (each simulation) will have one constant value for KT,
but a different KT will be randomly generated for every patient.
The maximal value of KT was calculated from in vitro data collected
by Vilar and colleagues (2006) on irinotecan concentration and growth
reduction of various colon cancer cell strains. We chose to use values
from the HT-29 cell line, as many of our other references used this
cell line also. We estimated five coordinates from a plot presented by
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Vilar’s team which gave irinotecan concentration (in mol/L) versus
growth of tumor cells, as a percentage of tumor cell growth with no
irinotecan. Since this was an in vitro study run over the course of only
a few days, we set all but tumor size and chemotherapy concentration
to zero and considered natural cell death to be zero. We also assumed
that chemotherapy concentration would be held constant, so dMdt = 0.
Thus our equation for tumor size becomes dTdt = −KT(1− e−δTM)T,
and so T = T0e−KT(1−e
−δTM)t. We converted the irinotecan concentra-
tion at each point to units of mg/L using 677 g/mol as the molec-
ular weight of irinotecan (Tsuruo et al., 1988). We then used tumor
sizes and chemotherapy concentrations from each point to write five
equations with δT and KT as unknowns. Since the system is overde-
termined (five equations, two unknowns), we chose values for δT and
KT that produced a reasonable fit. We found δT = 0.2 and KT ≈ 0.85.
KT was then separately confirmed by running multiple simulations
with our set of patient-specific parameter values to look for a tumor
response rate of approximately 10 percent after 6 weeks of treatment.
The reported response rate, the percentage of patients whose tumor
did not continue to grow after treatment, for irinotecan is around 30
percent, however patients receiving MAB treatment have usually al-
ready received a variety of chemotherapy treatments and did not re-
spond strongly to them (De Vita, Jr et al., 2000). Additionally, a 10
percent difference is reported between response rates for MAB ther-
apy alone and MAB/chemotherapy combinations, so we made this
percentage our goal instead of 30 percent (De Vita, Jr et al., 2000).
These simulations confirmed that a value of KT = 0.81 gives an aver-
age response rate of approximately 10 percent.
KAT = 4× 10−4 L mg−1day−1 for both cetuximab and panitumumab, is the
additional chemotherapy-induced tumor death due to MAB-tumor
interactions. Even with KAT set to zero, combination treatments give
us a response rate approximately 85 percent after 4 weeks of cetux-
imab and irinotecan treatments, and approximately 75 percent af-
ter 6 weeks of panitumumab and irinotecan treatments, compared to
the expected response rates of 22.5 percent for cetuximab/irinotecan
therapy and 20 percent for panitumumab/irinotecan therapy (De Vita,
Jr et al., 2000; Gravalos et al., 2009). However, it is known that MAB
therapy can help to increase chemotherapy responses in tumors, and
even restore partial response in chemotherapy-refractory tumors, and
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we chose a value of KAT = 4 × 10−4 (De Vita, Jr et al., 2000). At
maximal MAB concentrations, which are on the order of 102, this
will result in an increase in chemotherapy activity of approximately
4×10−4×102
8.1×10−1 ≈ .05 = 5%. If the simulations are run for 100 days with
KAT = 4× 10−4, we get an overall result of approximately 10 percent
of tumors reduced or eradicated, which seems reasonable.
δT = 2× 10−1 L mg−1, the medicine efficacy coefficient, was found as part
of the calculation for KT.
ψ = (2.28 × 10−2)y L mg−1day−1 for cetuximab and = (2.58 × 10−2)y
L mg−1day−1 for panitumumab is the rate of MAB-induced tumor
death, where y is a random variable with the same properties as x,
chosen for the same reasons (see description of KT and Figure 5.3).
Therefore, for cetuximab ψ ∈ [0, 2.28× 10−2], with a mean value of
1.71× 10−2, and for panitumumab ψ ∈ [0, 2.58× 10−2], with a mean
value of 1.94× 10−2. As with KT, multiplying the maximum value for
ψ by a random variable between zero and one allows us to represent
that each tumor has a different response to treatments. Each patient
(each simulation) will have one constant value for ψ, but a different
ψ will be randomly generated for every patient.
After other parameters for MAB monotherapy had been calculated,
the maximal value of ψ for each medication was found by running
simulations of MAB therapy as a single treatment over our set of
patient-specific parameters with a range of values for ψ, until we
achieved the desired response rate. We found ψ such that the re-
sponse rate for cetuximab after four weeks of treatment is 10 percent
and the response rate for panitumumab after six weeks of treatment
is 13 percent (De Vita, Jr et al., 2000).
5.3 dNdt : Natural Killer Cells
e
f =
1
9 , the ratio of the NK cell synthesis rate to the turnover rate, is found
using the same method as de Pillis’s team (2009). The value for ef is
found by assuming the no tumor equilibrium and thus setting Equa-
tion 4.2 to zero. We then ignore the term pNNIgN+I , which has only a very
small effect on NK proliferation It is approximately equal to the ra-
tio of NK cells/other lymphocytes, where other lymphocytes corre-
sponds to our C state and does not include activated T cells or NK
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cells. As in Section 5.1, NK cells make up approximately 10 percent
of all lymphocytes, and T cell count is negligible, giving us 10%90% , or
1
9 (Abbas and Lichtman, 2005).
f = 1× 10−2 day−1, the rate of NK cell turnover, is based on the value of
f = 1.25× 10−2 found by de Pillis and colleagues (2009). We lowered
the value slightly to agree with our assumption of a patient with a
weakened immune system, whose body may not be able to produce
new cells as quickly as normal healthy individual.
gN = 2.5036× 105 IU L−1, the concentration of IL-2 needed for half-maxi-
mal NK cell proliferation, is unchanged from the value found by
de Pillis’s team (2009).
pN = 5.13× 10−2 day−1, the rate of IL-2 induced NK cell proliferation, is
calculated using the same method as de Pillis’s team (2009). They
use data from Meropol and colleagues (1998) to find that 5.0073 ×
104 IU stimulates NK cells to reach a count of 2.3× 109 cells, and so
using these as I and N respectively and assuming T = 0, we then set
Equation 4.2 equal to zero and solve for pN :
pN =
f (N − ef C)(gN + I)
NI
.
Using C = 3× 109 from our no tumor equilibrium (see Section 5.1.1)
and the previously calculated values for e, f , and gN , we find that
pN = 5.13× 10−2.
p = 5.156 × 10−14 L cells−1 day−1, the rate of NK cell death due to tu-
mor interaction, is calculated using the same method as de Pillis’s
team (2009). We consider the large tumor equilibrium with no medica-
tion, which allows us to set Equations 4.1 and 4.2 equal to zero and to
solve for T and p:
p =
pNNI
gN+I
+ eC− f N
NT
and
0 = aT(1− bT)− cNT − DT
= aT(1− bT)− pNT − DT.
We were then able to use the values for pN , gN , e, f , a, b, the equation
for D with the parameters described in Section 6, and the state values
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for the immune system populations from the large tumor equilibrium
to find that T = 4.65928× 109 in the large tumor equilibrium and p =
5.156× 10−14.
pA = 6.5× 10−10 L cells−1day−1 for cetuximab and 0 for panitumumab is
the rate of NK cell death due to interactions with MAB-tumor com-
plexes. We set pA = ξ, under the approximation used for the parame-
ter c in Section 5.2 that for each tumor cell killed through ADCC, one
NK cell will also die.
KN = 9.048 × 10−1 day−1, the rate of NK depletion from chemotherapy
toxicity, is calculated using the same method as de Pillis’s team (2009),
by linearly scaling KC by the ratio of cell metabolic rates (see Sec-
tion 5.5 for KC calculation). That is,
KN =
f
β
KC.
δN = 2× 10−1 L mg−1, the chemotherapy toxicity coefficient, is assumed
to equal δT. The drug has a different efficacy (K) for each cell type,
but we assume that a similar concentration of irinotecan is needed to
affect each cell, regardless of cell type (de Pillis et al., 2009).
5.4 dLdt : CD8
+T cells
m = 5× 10−3 day−1, the rate of activated CD8+T-cell turnover, is based on
the value of m = 9× 10−3 found by de Pillis and colleagues (2009).
We lowered the value slightly to agree with our assumption of a pa-
tient with a weakened immune system, whose body may not be able
to produce new cells as quickly as normal healthy individual.
θ = 2.5036 × 10−3 IU L−1, the concentration of IL-2 to half CD8+T-cell
turnover, is unchanged from de Pillis and colleagues (2009).
q = 5.156 × 10−17 cells−1day−1, the rate of CD8+T-cell death due to tu-
mor interaction, is set equal to p× 10−3 because, as de Pillis and col-
leagues (2009) point out, we expect q to be approximately three or-
ders of magnitude less than p since L is approximately three orders
of magnitude less than N.
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r1 = 5.156× 10−12 cells−1day−1, the rate of NK-lysed tumor cell debris ac-
tivation of CD8+T cells, is calculated using the same method as de Pil-
lis’s team (2009). We set r1 = 100× c, based on the approximated a
lysed tumor cell can stimulated 10-300 T cells per day (de Pillis et al.,
2009).
r2 = 1× 10−15 cells−1day−1, the rate of CD8+T-cell production from cir-
culating lymphocytes, is based on the value of r2 = 5.8467× 10−13
found by de Pillis and colleagues (2009). We reduced it from their
value to reflect that a weak immune system may not be able to pro-
duce activated CD8 cells as effectively.
pI = 2.4036 day−1, the rate of IL-2 induced CD8+T-cell activation, was
found using the same method as de Pillis’s team (2009). A system
of equations was created by considering the no tumor equilibrium
and the large tumor equilibrium (see Sections 5.1.1 and 5.1.2). Set-
ting Equation 4.3 to zero and using to two sets of initial values for
T, N, L, C, and I, we can obtain two equations each with pI and u as
unknowns, and thus solve for the pI and u necessary to make satisfy
the equilibrium conditions.
gI = 2.5036 × 103 IU L−1, the concentration of IL-2 necessary for half-
maximal CD8+T-cell activation, is unchanged from the value found
by de Pillis’s team (2009).
u = 3.1718 × 10−14 L2 cells−2day−1, the CD8+T-cell self-limitation feed-
back coefficient, is obtained from the system of equations used to cal-
culated pI .
κ = 2.5036× 103 IU L−1, the concentration of IL-2 to halve the magnitude
of CD8+T-cell self-regulation, is unchanged from the value found by
de Pillis’s team (2009).
j = 1.245× 10−4 day−1, the rate of CD8+T-cell lysed tumor cell debris ac-
tivation of CD8+T cells, is based on the value of 1.245× 10−2 found
by de Pillis and colleagues (2009), and was decreased to indicate that
the weak immune system may not be able to activate CD8 cells as
effectively.
k = 2.019× 107 cells, the tumor size for half-maximal CD8+T-cell lysed tu-
mor debris CD8+T cell activation, is unchanged from the value found
by de Pillis’s team (2009).
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KL = 4.524× 10−1 day−1, the rate of CD8+T-cell depletion from chemother-
apy toxicity, is found in the same way as we found KN . We calculated
it using the same method as de Pillis’s team (2009), by linearly scaling
KC. That is,
KL =
m
β
KC.
δL = 2× 10−1 L mg−1, the chemotherapy toxicity coefficient, is found in
the same way as we found δN . We assumed it to be equal to δT (de Pil-
lis et al., 2009).
5.5 dCdt : Lymphocytes
α
β = 3× 109 cells L−1, the ratio of the rate of circulating lymphocyte pro-
duction to turnover rate, is taken from considering the steady state
assumption of dCdt = 0 in a healthy, tumor free individual. Consider-
ing Equation 4.4 with M = 0, we find that αβ = C, where C = 3× 109
refers to the equilibrium value of C in the no tumor equilibrium (see
Section 5.1).
β = 6.3× 10−3 day−1, the rate of lymphocyte turnover, is unchanged from
the value found by de Pillis’s team (2009).
KC = 5.7× 10−1 day−1, the rate of lymphocyte depletion from chemother-
apy toxicity, was calculated to achieve the results given by Catimel
and colleagues (1995) on the number of patients with leukopenia after
irinotecan treatments. Catimel’s team found that when 100 mg/m2
was given to patients daily for three days, three out of eleven patients
had leukopenia, and when 115 mg/m2 was given daily for three days,
four out of ten patients had leukopenia. We assumed that the normal
leukocyte count is 4.5− 11× 109 cells/L, and lymphocytes can make
up 16-46 percent of the total leukocytes in the body (Abbas and Licht-
man, 2005). Thus, we calculate that the normal lymphocyte count
is 0.72− 5.06× 109 cells/L. A patient is considered to have leukope-
nia when the leukocyte count drops below 1.9 × 109 (Welink et al.,
1999), and so the highest possible lymphocyte count in a patient with
leukopenia is 46 percent of 1.9× 109, or 8.74× 108 cells. We will as-
sume that the lymphocyte count for all patients will drop equally,
and so those who begin intially with a lower lymphocyte count will
become leukopenic, and those who begin with a higher lymphocyte
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count will have a reduced cell count, but will remain within the nor-
mal range. So, the lowest three elevenths of patients will have lym-
phocyte levels below 1.904× 109 cells, and the lowest four tenths of
patients will have lymphocyte levels below 2.456× 109 cells. We ran
simulations considering only lymphocyte counts, with irinotecan de-
livered once daily over 1.5 hours for a total of 3 days, and found a
value for KC that made an initial lymphocyte count of 1.904 × 109
drop to approximately 8.74× 108 with a 100 mg/m2 dose and an ini-
tial lymphocyte count of 2.456× 109 drop to approximately 8.74× 108
with a 115 mg/m2 dose. The two doses resulted in KC values of 0.52
and 0.63 respectively, so these were averaged to find KC = .57.
δC = 2× 10−1 L mg−1, the chemotherapy toxicity coefficient, is found in
the same way as we found δL. We assumed it to be equal to δT (de Pil-
lis et al., 2009).
5.6 dMdt : Irinotecan Chemotherapy Treatment
γ = 4.077× 10−1 day−1, the rate of excretion and elimination of chemother-
apy drug, is calculated using the assumption of exponential decay
from ln(2)t1/2 , where t1/2 is the half-life of SN-38, the active form of irinote-
can, in tissue. We found that the half-life of irinotecan in rat tissue is
7.2 hours, the half life of irinotecan in rat plasma is 1.8 hours, the
half life of irinotecan in human plasma is 8.3 hours, and the half life
of SN-38 in human plasma is 10.2 hours (Noble et al., 2006; Catimel
et al., 1995). We then assume that the ratio of the irinotecan half life
in rat tissue/rat plasma equals the ratio of irinotecan half life in hu-
man tissue/human plasma, to get that the half life of irinotecan in
human tissue is 7.2 × 8.3/1.8 = 33.2 hours. We also assume that
the ratio of irinotecan half life in human tissue/plasma equals the
SN-38 half life in human tissue/plasma, which gives us that the half
life of SN-38 in human tissue is 33.2× 10.2/8.3 = 40.8 hours. Thus
γ = ln(2)40.8/24 = 4.077× 10−1.
5.7 dIdt : Interleukin
µI = 11.7427 day−1, the rate of excretion and elimination of IL-2, is un-
changed from the value found by de Pillis’s team (2009).
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ω = 7.88× 10−2 IU cells−1day−1, the rate of IL-2 production from CD8+T
cells, is calculated using the same method as de Pillis’s team (2009),
from the no tumor and large tumor equilibria. dIdt is set to zero, and the
known parameters and initial values are used to find two equations
with ω and φ unknown. These two parameters can then be solved
for.
φ = 1.788× 10−7 IU cells−1day−1, the rate of IL-2 production from CD4+
and naive CD8+T-cell IL-2 production, is found as part of the system
of equations solving for ω.
ζ = 2.5036× 103 IU L−1, the concentration of IL-2 for half-maximal CD8+T-
cell IL-2 production, is unchanged from the value found by de Pillis’s
team (2009).
5.8 dAdt : Cetuximab and Panitumumab Monoclonal An-
tibody Treatment
η = 1.386 × 10−1 day−1 for cetuximab and 9.242 × 10−2 day−1 for pani-
tumumab is the rate of MAB turnover and excretion. The parameter
η is calculated using the assumption of exponential decay from ln(2)t1/2 ,
where t1/2 is the half-life in tissue of each MAB. For cetuximab, the
half life in tissue is 5 days, so η = ln(2)5 = 0.139 (Grothey, 2006).
For panitumumab, the half life in tissue is 7.5 days, so η = ln(2)7.5 =
0.092 (Grothey, 2006).
λ = 8.3 × 10−14 mg cells−1L−1day−1 for cetuximab and 8.6 × 10−14 mg
cells−1L−1 day−1 for panitumumab is the rate of MAB/tumor-cell
complex formation. Average cells have around 20,000 EGFRs (Amer-
ican Association for Cancer Research, 2010). The binding affinity of
cetuximab is 400 pM (picomolar, which measures the ratio of the
concentration of unbound molecules to the concentration of bound
molecules) and for panitumumab it is 50 pM (Freeman et al., 2008).
We will first consider cetuximab, which has a molecular weight of 152
kD=152× 106 mg/mol (RxList, 2009a). A binding affinity of 400 pM
means that 400 pM = [cetuximab][EGFRs]/[cetuximab-EGFR com-
plexes]. To find the number of cetuximab-EGFR complexes per cell,
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we first converted 400 pM to units of mg/L:
400 pmol
1L
× 1 mol
1012 pmol
× 152× 10
6 mg
1mol
= 6.08× 10−2 mg/L.
This is approximately one sixteenth, so for each free cetuximab molecule
and EGFR, there are about sixteen cetuximab-EGFR complexes. So,
out of 20,000 EGFRs, approximately 1250 of them will be free, and
therefore 18750 cetuximab molecules will be lost for each tumor cell
lost. We can convert this back into concentration of cetuximab lost
per tumor cell:
18, 750 MABs× 1 mol
6× 1023 MABs ×
152× 106 mg
1 mol
× 1
57L
= 8.3× 10−14 mg/L.
Thus, for cetuximab, λ = 8.3× 10−14. For panitumumab, we will do
a similar computation, using instead panitumumab’s binding affin-
ity and its molecular weight of 147 kD=147 × 106 mg/mol (RxList,
2009b). We will first change units on the binding affinity to the units
of panitumumab concentration:
50 pmol
1L
× 1 mol
1012 pmol
× 147× 10
6 mg
1mol
= 7.35× 10−3 mg/L.
This is approximately 1136 , so for each free panitumumab molecule
and EGFR, there are about 136 panitumumab-EGFR complexes. So,
out of 20,000 EGFRs, approximately 147 of them will be free, and
therefore about 19,850 panitumumab molecules will be lost for each
tumor cell lost. We can convert this back into mg of panitumumab
lost per tumor cell:
19, 850 MABs× 1 mol
6× 1023 MABs ×
147× 106 mg
1 mol
× 1
57L
= 8.6× 10−14 mg/L.
Thus for panitumumab, λ = 8.6× 10−14.
h2 = 4× 10−5 mg L−1 for cetuximab and 4.05× 10−5 mg L−1 for panitu-
mumab is the concentration of MABs for half-maximal EGFR bind-
ing. We will first consider cetuximab, and will use 109 as the number
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of tumor cells and 57 L as the volume of an average person (de Pillis
et al., 2009). Assuming that 18,750 cetuximab molecules bind to each
tumor cell, we want to find the number of mg/L at which the EGFRs
are saturated:
18, 750 MAB
1 cell
× 109 tumor cells× 1 mol
6× 1023 MAB×
152× 106 mg
1 mol
× 1
57 L
= 8.0× 10−5 mg/L.
So, we will set h2 = 0.5× 8× 10−5 = 4× 10−5 mg/L for cetuximab.
We will do a similar computation for panitumumab, using instead
19,850 MABs for each cell:
19850 MAB
1 cell
× 109 tumor cells× 1 mol
6× 1023 MAB×
147× 106 mg
1 mol
× 1
57 L
= 8.1× 10−5 mg/L.
Thus we will set h2 = 0.5× 8.1× 10−5 = 4.05× 10−5 mg/L for pani-
tumumab.
5.9 Treatments
In this section we show the calculations performed to find the treatment
functions (vL, vM and vA) for the most commonly used treatment sched-
ules. In Sections 6.2 and 6.3, we will also use other dosing schedules, which
will be calculated in the same way. Unless otherwise noted, the treatment
regimens have been adapted from De Vita’s book titled Cancer: Principles
and Practice of Oncology (2000).
5.9.1 Activated CD8+T-Cell Treatments
vL (IU/L/day) is unchanged from 1.44 × 1010 IU/L/day, the dose calcu-
lated by de Pillis and colleagues (2009). We would like to give this dose
over 1 hour=0.04167 days (see Figure 5.5), so we want to set
vL(t) =
{
4.248× 1011 IU/L/day if t ∈ {0, 0.04167},
0 otherwise.
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Figure 5.4: Activated CD8+T-cell treatment, given only on the first day of
treatment.
Figure 5.5: Irinotecan dosing schedule for the first 10 days of treatment.
Note that spikes in medication level are slightly offset (by 1/12 days) from
day 0 and 7.
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5.9.2 Irinotecan Treatments
vM (mg/L/day) has been changed to fit a common treatment regimen for
irinotecan. A 125 mg/m2 dose of irinotecan is usually given over 90 min-
utes once weekly (see Figure 5.5). We assume that the course lasts for 6
weeks. Because the irinotecan molecule must be converted to an active
form in the body before it can be used, the effect has a two-hour delay. We
assume 1.73 m2 to be the average surface area of an adult (Ratain, 1998). Be-
cause the medication quickly leaves the blood stream, we will use 59.71 L,
the average volume of an adult, as the volume over which the medication
is spread (de Pillis et al., 2009). So, we would like each dose to infuse
125
mg
m2
× 1.73 m2 × (59.71 L)−1 = 3.6217 mg/L,
and because it will be given over 90 minutes=0.0625 days, we want to set
vM(t) =
{
57.947 mg/L/day if treatment was given at time (t− 2/24),
0 otherwise.
We check for treatments at time (t− 2/24) because irinotecan needs to
be converted by the body to its active form, SN-38, and SN-38 levels reach
their peak two hours after irinotecan levels (De Vita, Jr et al., 2000).
5.9.3 Cetuximab Treatments
For cetuximab, a loading dose of 400 mg/m2 is usually given over two
hours, followed by a weekly 250 mg/m2 dose over 60 minutes (see Fig-
ure 5.6(a)). Cetuximab is given on a six-week periodic schedule, during
which it is given weekly for the first four weeks, then not given for two
weeks. We will assume the same surface area and volume as in Section 5.6.
For the loading dose, we would like to infuse
400
mg
m2
× 1.73 m2 × (59.71 L)−1 = 11.59 mg/L,
and because it will be given over two hours=0.0833 days, we want to set
vA(t) =
11.59 mg/L
0.0833 days
= 139.072
for the first two hours of the simulations. For the regular weekly treat-
ments, we would like to infuse
250
mg
m2
× 1.73 m2 × (59.71 L)−1 = 7.243 mg/L,
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(a) Cetuximab dosing schedule for the
first 10 days of treatment. Note the dif-
ferent size of the initial loading dose.
(b) Panitumumab dosing schedule dur-
ing the first 15 days of treatment.
Figure 5.6: Monoclonal antibody dosing schedules.
and because it will be given over 60 minutes=0.04167 days, we want to set
vA(t) =
7.243 mg/L
0.04167 days
= 173.840.
Thus, at any time t,
vA(t) =

139.072 mg/L/day if t ∈ (0, 224 )
173.840 mg/L/day if treatment was given at time t & t ≥ 224
0 if treatment was not given at time t.
5.9.4 Panitumumab Treatments
The value of vA for panitumumab was found in the same way, except that
panitumumab does not require a loading dose (Figure 5.6(b)). We assume
a treatment regimen of 6 mg/kg every two weeks, for a total of three treat-
ments. We assume that the medication is given over 60 minutes, and that
an average adult weighs of 70 kg (Lewis, 2009). This gives us
vA(t) =
{
168.816 mg/L/day if treatment was given at time t
0 if treatment was not given at time t.
Chapter 6
Results and Analysis
In our simulations, we use the initial conditions discussed in Section 5.1.3:
N = 9× 107, L = 5× 104, C = 109, M = 0, I = 1173, A = 0,
and we fix our initial tumor size at T = 109 cells. Most of the tumors being
treated with MAB therapy have already been growing for a long time, so
we expect them to initially be large. However, we also wanted allow for the
tumors to continue growing in our simulations. Thus, we chose a conve-
nient initial tumor size that is about 20-25 percent of the carrying capacity.
In Sections 6.1, 6.2, and 6.3, we fix the patient-specific parameters d, l,
and s at d = 1.9, l = 1.6, and s = 7 × 10−3 to make it possible to plot
sample results. For these plots of a single patient receiving one course of
medication, we set KT and ψ to values at both the low and high end of their
ranges. This allows us to more easily show the range of possible results,
and to know what response strength our plot represents. Each tumor (and
therefore each patient) has only one value for each of KT and ψ, so the
simulations that result from setting these parameters are possible plots that
can be generated when the values are generated randomly; setting KT and
ψ only speeds up the process of getting varied results. The importance of
allowing KT and ψ to vary arises in our simulations of clinical trials with
our 64 different patients, because the tumors of each of these patients will
respond differently to the medications due to the properties of the tumor,
separate from the properties of the patient’s immune system.
We use three values for KT and ψ: 10 percent of the maximum response
to represent a weak response, 75 percent of the maximum response (the
expected value of the variables) to represent a moderate response, and 100
percent of the maximum response to represent a strong response.
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6.1 Current Monotherapies
We plotted irinotecan, cetuximab, and panitumumab as monotherapies,
for tumors with either a weak or strong reaction to the medication. For
irinotecan, we can see that if the tumor has a weak response to irinotecan
it will quickly grow. If the tumor has a strong response to the medication,
it will grow slightly, but while growing will exhibit a strong oscillation in
cell count, corresponding to treatments (see Figure 6.1).
Similarly, we see that if the tumor has a weak response to cetuximab it
will quickly grow. If the tumor has a strong response to the medication,
it will again grow slightly, but while growing will exhibit a strong oscilla-
tion in cell count, corresponding to treatments (see Figure 6.2). For pan-
itumumab, we see tumor growth similar to growth with cetuximab treat-
ments, for both a strong and weak response (see Figure 6.3).
6.2 Current Combination Treatments
We plotted combination therapies of irinotecan, cetuximab or panitumum-
ab, and activated CD8+T-cell treatments for tumors with either a weak or
strong reaction to chemotherapy and, separately, MAB therapy. When a
tumor does not respond strongly to either treatment, the tumor will quickly
grow to the carrying capacity (see Figure 6.4).
When the tumor responds weakly to one of the medications but strongly
to the other, the tumor does not grow as quickly as when it has a weak re-
sponse to both medications, but we are still unable to eradicate the tumor
completely (see Figure 6.5).
When the tumor responds strongly to both medications, we see that for
this set of patient-specific parameters, d = 1.9, l = 1.6, s = 7× 10−3, a ce-
tuximab/irinotecan combination treatment and a panitumumab/irinotecan
combination treatment are both able to significantly shrink the tumor (see
Figure 6.6), but neither can eradicate it completely. However, for patient-
specific parameters representing a patient with a slightly stronger immune
system (recall from Section 5.2 that a stronger immune system is indicated
by a low l and s and a high value for d), these treatment combinations can
eradicate the tumor. For example, if we set l = 1.3 instead of 1.6 and s =
4× 10−3 instead of 7× 10−3 while leaving all other parameters and starting
values the same, the cetuximab/irinotecan combination treatment (see Fig-
ure 6.7(a)) and the panitumumab/irinotecan combination treatment (see
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(a) Linear plot and log plot of a weak tumor response.
(b) Linear plot and log plot of a strong tumor response.
Figure 6.1: Tumor response to irinotecan monotherapies.
(a) Linear plot and log plot of a weak tumor response.
(b) Linear plot and log plot of a strong tumor response.
Figure 6.2: Tumor response to cetuximab monotherapies.
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(a) Linear plot and log plot of a weak tumor response.
(b) Linear plot and log plot of a strong tumor response.
Figure 6.3: Tumor response to panitumumab monotherapies.
Figure 6.7(b)) both successfully reduce tumor size enough that the tumor
approaches the no tumor equilibrium (see Figure 6.7(a)).
With our model, we can also simulate clinical trials with multiple pa-
tients and examine the overall response rates. For the most common treat-
ment regiments, using the vL, vM, and vA calculated in Section 5.9, we
found the response rates shown in Table 6.1. Our response rates are sepa-
rated into “Partial Response”, meaning the tumor shrank but was not erad-
icated, and “Complete Response”, meaning the tumor was reduced enough
to be attracted to the no tumor equilibrium. For monotherapies, our response
rates match those of clinical trials very closely. For combination therapies,
the responses from our model one week after the first treatment ended were
much stronger than those seen in clinical trials. However, clinical trials are
not consistent in the number of days between trial completion and deter-
mining the effect of the medication. If we measure the response rates for
our simulations after seven weeks, when patients have had a few weeks of
no treatment and doctors are likely to be evaluating whether or not to con-
tinue with an additional treatment course, we end up with response rates
very similar to those found in clinical trials. After seven weeks, our pa-
tients on cetuximab/irinotecan have an overall response rate of 16 percent,
and our patients on panitumumab/irinotecan have a response rate of 21
percent.
Current Combination Treatments 45
(a) Linear plot and log plot of a weak tumor response to
irinotecan and cetuximab.
(b) Linear plot and log plot of a weak tumor response to
irinotecan and panitumumab.
Figure 6.4: Weak tumor response to irinotecan and MABs in combination
therapy.
(a) Linear plot and log plot of a weak tumor response to
irinotecan and a strong response to cetuximab.
(b) Linear plot and log plot of a strong tumor response to
irinotecan and a weak response to cetuximab.
Figure 6.5: Strong tumor response to only one medication in combination
therapy with cetuximab.
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(a) Linear plot and log plot of a strong tumor response to
irinotecan and to cetuximab.
(b) Linear plot and log plot of a strong tumor response to
irinotecan and to panitumumab.
Figure 6.6: Strong tumor response to irinotecan and MABs in combination
therapy.
(a) Linear plot and log plot of response to cetuximab and
irinotecan.
(b) Linear plot and log plot of response to panitumumab
and irinotecan.
Figure 6.7: Strong tumor response to the medications, with l = 1.3 and
s = 4× 10−3.
C
urrentC
om
bination
Treatm
ents
47
Medicationa Our Results Published Results Source
Name Dose Freq. N PR CR N PR CR
Irinotecan 125 mg/m2 q1w 320 6.9% 1.3% noneb
Cmab 400 mg/m2 load & 320 10.0% <1% NP 9-11% NP De Vita, Jr et al. (2000)
250 mg/m2 q1w 346 11.6% NP Lenz (2007)
111 10.8% 0% Cunningham et al. (2004)
Pmab 6 mg/kg q2w 320 13.1% <1% NP 13% NP De Vita, Jr et al. (2000)
231 10% NP Gravalos et al. (2009)
Irinotecan 125 mg/m2 q1w, 320d 68.4% 10.9% NP 22.5-9% NP De Vita, Jr et al. (2000)
and Cmab 400 mg/m2 load, 320 5% 10.9% NP 23% NP Grothey (2006)
250 mg/m2 q1w NP 22.9% 0% Cunningham et al. (2004)c
Irinotecan 350 mg/m2 q3w, 320 64.4% 17.5% 648 15% 1.4% Sobrero et al. (2008)
and Cmab 400 mg/m2 load,
250 mg/m2 q1w
Irinotecan 125 mg/m2 q1w, 320d 56.0% 10.6% 34 20% NP Gravalos et al. (2009)c
and Pmab 6 mg/kg q2w 320 9.1% 11.9%
Table 6.1: Response rates to common treatment schedules.
aAbbreviations: Pmab=panitumumab; Cmab=cetuximab; q1w=every week; q2w=every two weeks; q2w=every three weeks;
load=loading dose; N=number of patients; PR=partial response; CR=complete response; NP=not provided.
bMost response rates for irinotecan found in the literature are for irinotecan as a first-line treatment. However, patients receiving MAB
therapy are usually receiving it because they did not respond well to chemotherapy (Cunningham et al., 2004).
cIrinotecan dosing schedule was varied during the study.
dThe first response rates (RRs) are measured 7 days after completion of first treatment. The second RRs for each are measured 7 weeks
after treatment began.
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6.3 Tumor Growth With Experimental Treatments
Since the responses of our combination therapies in the model are stronger
than the results we see in clinical trials, we will compare the results of ex-
perimental treatments to those of the treatment schedules found in Sec-
tion 5.9. This results in one treatment schedule each for panitumumab/iri-
notecan and cetuximab/irinotecan, which will be referred to in this section
as the “standard treatments”. For each experimental treatment tested, we
first looked at whether it increased or decreased final tumor size from the
response to the standard treatments. Since we wanted to see the change in
response of one patient’s tumor under each treatment, we fixed the patient-
specific parameters to those given in Section 6 and KT and ψ to 75 percent
strength. Once treatments were identified which reduced final tumor size,
we ran a clinical trial simulation on the treatment, and compared the re-
sponses to those of the standard treatment.
We currently do not have “patient health” (e.g., quality of life, negative
side effects of the drugs, inconvenience of treatments) built into the model,
so we used lymphocyte count to determine whether a treatment is valid.
Grade 4 leukopenia, which indicates the worst depletion of leukocytes, is
considered to be any leukocyte count below 1× 109 cells/L (Welink et al.,
1999). We use 16 percent, the low end of the range for percent of leukocytes
that are classified as lymphocytes, as reported in Section 5.5, and consider
only the 90 percent of those lymphocytes which are not NK cells or CD8+T
cells. This gives us 1.44× 108 as the lowest possible value for C that avoids
grade four leukopenia, so any treatments resulting in a lymphocyte count
below this number for any patient are considered invalid.
We have found two treatment schedules for each medication that give
improved results over the standard treatments (see Table 6.2). For the first,
we left the doses and administrating frequencies the same, but begin the ce-
tuximab and panitumumab treatments four days after the cetuximab treat-
ments. Interestingly, although starting the MAB treatment 4 days late was
an improvement, beginning the chemotherapy 4 days after the MAB treat-
ments gave a slightly worse outcome (<1 percent increase in final tumor
size for cetuximab, 2 percent increase in final tumor size for panitumumab).
For cetuximab, we saw only a small decrease in tumor size of approxi-
mately 1 percent, and only a slight increase of an additional 6 percent of pa-
tients had a partial response in the clinical trial simulation (see Figure 6.8).
For panitumumab, we saw a 19 percent decrease in final tumor size, and an
additional 14 percent of patients had a partial response to the medication,
but again no increase in patients with a complete response (see Figure 6.9).
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(a) Linear plot. (b) Log plot.
Figure 6.8: Cetuximab treatments started at t = 4 days.
(a) Linear plot. (b) Log plot.
Figure 6.9: Panitumumab treatments started at t = 4 days.
(a) Linear plot. (b) Log plot.
Figure 6.10: High dose irinotecan and cetuximab treatments.
(a) Linear plot. (b) Log plot.
Figure 6.11: High dose irinotecan and panitumumab treatments.
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Medication Our Resultsa
Nameb Dose Frequencyc N PR CR
Irinotecand 125 mg/m2 weekly, 320 68.44% 10.94%
and Cmab 400 mg/m2 load &
250 mg/m2 weekly
Irinotecand 125 mg/m2 weekly & 320 56.00% 10.63%
and Pmab 6 mg/kg q2w
Irinotecan 125 mg/m2 weekly & 320 74.06% 10.94%
and Cmab 400 mg/m2 load, day 4 &
250 mg/m2 weekly
Irinotecan 125 mg/m2 weekly & 320 70.99% 10.31%
and Pmab 6 mg/kg q2w, day 4
Irinotecan 350 mg/m2 q3w 320 52.19% 37.5%
and Cmab 350 mg/m2 q2w
and Pmab 9 mg/kg q3w
aN=number of patients; PR=partial response; CR=complete response.
bPmab=panitumumab; Cmab=cetuximab
cq3w=every three weeks; q2w=every two weeks; load=loading dose.
dThe standard treatments.
Table 6.2: Response rates to our experimental treatment schedules.
The second improved treatment schedule gives patients a high dose
of both medications given less frequently. The high dose treatments have
been used occasionally as a monotherapy, but to our knowledge have not
been combined. Irinotecan can be given as a dose of 350 mg/m2 every
three weeks without additional side effects for the patient, so we use this
as our irinotecan dose Sobrero et al. (2008); Lenz (2007). We first combined
this with a high dosing schedule for cetuximab of 350 mg/m2 every other
week (Lenz, 2007). This dosing schedule resulted in a decrease in final tu-
mor size of 39 percent from the standard treatment, and an additional 25
percent of the patients had a complete response to the treatment (see Fig-
ure 6.10). We next combined the high irinotecan dose with a 9 mg/kg dose
given every 3 weeks (Gravalos et al., 2009). This dosing schedule results
in a decrease in final tumor size of 34 percent from the standard treatment,
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and an additional 7 percent of the patients had a complete response to the
treatment (see Figure 6.11).
6.4 Sensitivity to Parameters
Parameter sensitivity analysis was performed to determine which model
parameters have the biggest effect on final tumor size. First, sensitivity to
non medication parameters was examined in simulations with no medica-
tion given. Each parameter value was increased and decreased by 5 per-
cent, and the tumor size was measured at 5 days and 20 days, at which
times the tumor is still growing very quickly and is close to its maximum
volume, respectively, in our model (see Figure 6.12). Note that, while b
(which, unsurprisingly, represents the inverse of the carrying capacity) is
by far the most important parameter in determining final tumor size, a (the
exponential tumor growth rate) plays a much more important role in deter-
mining how quickly the tumor reaches its maximum volume. The parame-
ter l, an immune system scaling factor, is also important in determining the
tumor growth rate.
The sensitivity of the model to the MAB parameters was also examined.
For both cetuximab and panitumumab, the final tumor size was found to
be sensitive to ψ, the strength of the tumor’s response to MAB drugs, and
to η, the MAB turnover rate (see Figures 6.13 and 6.14). This is expected,
since the main anti-tumor activity of MAB medications is through interfer-
ence with the ability of EGF to bind to EGFR on the tumor cell surface, an
activity which is included in the term ψ (De Vita, Jr et al., 2000). Short term,
cetuximab also shows some sensitivity to ξ and pA, which are the parame-
ters that determine the strength of ADCC activity (see Figure 6.13(a)).
We also checked the sensitivity of the model to the chemotherapy pa-
rameters. The final tumor size was found to be very sensitive to KT and
δT, which determine the model’s response to chemotherapy, and γ, which
represents the excretion of the chemotherapy drug (see Figure 6.15). The
size of the peak in tumor volume between treatments was much more de-
pendent on γ than the size of the nadir after treatments. This makes sense,
because if the chemotherapy is able to last longer in the body, it will be
more effective at maintaining lower tumor volumes between treatments.
Finally, we also checked the sensitivity of the model to the parameter
KTA, which represents the increase in effectiveness of chemotherapy when
it is used in conjunction with MAB therapy. With a 5 percent increase and
decrease in the value of KTA, the final tumor size after 28 days changed by
less than 0.5 percent (figure not shown).
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(a) Final tumor size measured at 5 days.
(b) Final tumor size measured at 20 days.
Figure 6.12: Sensitivity of final tumor size to a 5% change in non-
medication parameters.
(a) Change in tumor growth after 7
days.
(b) Change in tumor growth after 28
days.
Figure 6.13: Sensitivity of final tumor size to a 5% change in cetuximab
parameters.
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Figure 6.14: Sensitivity of final tumor size to a 5% change in panitumumab
parameters after 35 days.
(a) Change in tumor growth after 4
days.
(b) Change in tumor growth after 35
days.
Figure 6.15: Sensitivity of final tumor size to a 5% change in irinotecan
parameters.

Chapter 7
Discussion
We have edited the model of de Pillis and colleagues (2009) to include
monoclonal antibody treatment, and we have found, calculated, or esti-
mated parameter values to make the model specific for colorectal cancer,
the chemotherapy treatment irinotecan, and the monoclonal antibodies ce-
tuximab and panitumumab. We have found two separate stable equilib-
rium states, a no tumor equilibrium and a large tumor equilibrium, and seen
that tumors can be driven to either of these states, depending on the pa-
tient’s immune system and the treatments given. We have also added two
parameters that are constant for each patient (within each individual simu-
lation run), but can be randomly generated for each tumor at the beginning
of the simulation. These parameters, KT and ψ, represent the range of dif-
ferent tumor responses to the same chemotherapy and MAB treatments.
Colorectal tumors can have a wide variety of mutations, and some of these
mutations limit the medication’s ability to function correctly. Besides mak-
ing biological sense, these randomly chosen variables helped us to achieve
the results seen in clinical trials.
When our model is run over our set of 64 “patients,” our model matches
clinical trials for monotherapy very well. For combination therapies, our
tumor population seems to often be too response to the medication, how-
ever this could likely be fixed if more work was done on choosing a more
accurate way to model the variance in tumor responses. Also, if response
rates are measured a few weeks after the treatments have finished, which
might be done if tumor size is measured to determine additional treatments
instead of to measure the effectiveness of the previous medication, then
our results match the results of the clinical trials very closely. We find a
16 percent response rate for cetuximab/irinotecan, compared to 22 percent
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response rate found in clinical trials (De Vita, Jr et al., 2000), and a 21 per-
cent response rate for panitumumab/irinotecan, compared to a 20 percent
response rate found in clinical trials (Gravalos et al., 2009). However, for
panitumumab/irinotecan combination therapies, very few clinical trial re-
sults are available. Multiple clinical trial results are available for cetuximab,
but many do not specify irinotecan dosing (or use a variety of doses), and
many also do not specify whether the patient has received treatment previ-
ously, how long the treatment was given, and other useful information. We
are confident that overall, our model gives a qualitatively good prediction
of likely results for various dosing schedules.
Many of the combination treatments we experimented with, which used
different doses, dosing frequencies, and different start times for each med-
ication, were not as successful at shrinking the tumor as the current stan-
dard treatments. However, we did find two treatments which appear to
provide a better outcome for the patients. One of these, which provided
only minor improvements, required offsetting the MAB medication admin-
istration by 4 days from the chemotherapy. This treatment plan, which does
not require a change in dose size or frequency, resulted in more patients
with partial responses to the medications. This treatment plan may also
help to reduce the strength of the negative side affects associated with each
of these medications. However, it also requires the patient to receive treat-
ment twice a week for at least an hour, and this inconvenience may offset
the other potential benefits.
We also found a treatment option that combined a higher dose of the
drugs administered less frequently. This treatment option was very suc-
cessful in our model, and particularly for the irinotecan/cetuximab treat-
ment, allowed for many more patients to reach the no tumor equilibrium.
The resulting lymphocyte count from this treatment was barely above the
lymphocyte count that we considered to be unacceptably low (1.44× 108
versus 1.47× 108), so it is possible that in practice this particular treatment
would be too harsh for the patient. However, variations on this treatment
may be worth exploring in a clinical setting, especially if supportive care is
available or the patient is starting out healthier than the patients we con-
sidered. Each of the three treatments (less frequent, high dose cetuximab,
panitumumab, and irinotecan) individually causes large dips and spikes in
tumor cell count, so one feature that was particularly useful about this ce-
tuximab/irinotecan combination, compared to other cetuximab/irinotecan
combinations that we looked at, was that the high dose cetuximab is given
every two weeks, whereas the high dose irinotecan is given every three
weeks, so the treatments are not always given at the same time and are able
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to work together to keep the tumor population low. Neither giving pani-
tumumab every two weeks nor offsetting the higher dose panitumumab to
alternate weeks with the irinotecan had this same effect, although it’s pos-
sible that a higher dose of panitumumab may be able to achieve this. A
treatment schedule like this would also be convenient for the patient, be-
cause medication (and the negative side effects that come with it) would be
required less frequently.
The parameter sensitivity did not provide any particularly surprising
results, however it is useful to think about which parameters could be pos-
sible targets for reducing tumor size. For example, if we can get a better
sense of biologically how to influence l, a large decrease in l would result
in an immune system that is able to conquer the tumor much more easily
than a change in the other immune system parameters.
In the future, it would be very helpful to make two important changes
to the model. First, it would be helpful to tailor the parameters KT and
ψ to have a more specific biological meaning. For example, the KRAS
mutation is known to be present in about 40 percent of all colorectal tu-
mors, and is known to reduce the effectivness of MAB treatment to almost
zero (De Roock et al., 2008; Amado et al., 2008). Collecting information on
how factors such as whether the tumor is a KRAS mutant and the EGRF
counts on the tumor cells could allow for these parameters to be chosen
from a small distribution based on features of the tumors cells, instead of
from a larger random distribution. Also, an equation representing patient
well-being would be very useful for predicting effective treatments. Al-
though using lymphocyte count allows us to determine that the patient’s
immune system has not been completely destroyed by the medication, it
doesn’t take into account factors such as that frequent treatments may be
inconvenient or that high doses of medication also results in stronger harm-
ful side effects.

Appendix A
Biology Glossary
Unless otherwise stated, all definitions are from Sompayrac’s How the Im-
mune System Works (2008).
Adaptive immune system The part of our immune system that is targeted
for a specific invader. It is slow to activate but an effective killer.
Antibody Proteins that help the adaptive immune system by targeting a
particular invader and then helping the NK cells to find it.
Antibody-dependent cellular cytotoxicity Antibody-directed killing of tu-
mor cells by natural killer cells. The antibodies activate the NK cells
and direct connect them to their target.
Antigen The target of an antibody’s or T cell’s search, such as a protein on
an invading cell.
Apoptosis The process during which a cell commits suicide, either due to
problems within the cell or signals from another cell.
B cell Lymphocytes that can produce antibodies.
Binding affinity How tightly two molecules bind together. Can be repre-
sented by the dissociation constant (with units of molarity=M=mol/L),
which is the concentrations of the separate molecules divided by the
concentrations of the complexes, so a smaller dissociate constant means
that the molecules bind together more tightly (Voet et al., 2008).
Chemotherapy Chemotherapeutic drugs kill off rapidly dividing cells (Som-
payrac, 2004).
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Complement system The complement system is a protein cascade that is
activated when invaders are present. These proteins help to recruit
other cells to the kill the invaders. In some cases, they can also destroy
invading cells themselves, as in complement-dependent cytotoxicity.
Also called the complement cascade.
Complete response The disappearance of all signs of cancer in response to
treatment (National Cancer Institute, 2010).
Cytokines Messenger molecules that cells use to communicate.
Dendritic cell Leukocytes that present antigens to T cells to let them know
what to target.
Epidermal growth factor A protein made in the body with causes cells to
grow and mature. It is a type of cytokine (National Cancer Institute,
2010).
Epidermal growth factor receptor A protein found on the surface of some
cells, to which the epidermal growth factor binds to cause cell prolif-
eration. It is found in abnormally high levels on many types of cancer
cells (National Cancer Institute, 2010).
Extracellular domain The part of a receptor that sticks out of the cell (Na-
tional Cancer Institute, 2010).
Homeostasis A steady state condition in the body, in which concentrations
are remaining constant (Voet et al., 2008).
Innate immune system The part of our immune system which is always
prepared to fight invaders, without activation.
Interleukin-2 A cytokine that is used as communication between leuko-
cytes.
In vitro A study conducted in a controlled (lab) environment, usually in
cultured cells (Voet et al., 2008).
In vivo A study conducted in a living organism, usually referring to ani-
mal testing or clinical trials (Voet et al., 2008).
Leukocyte White blood cells, the cells that make up our immune system.
Lymphocyte One type of leukocyte, make up to T cells and B cells
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Metastasize When tumors have metastasized, it means that the tumor cells
have spread to new locations in the body and have begun to grow
new tumors.
MHC proteins The presence of the proper MHC proteins on the surfaces
of our cells helps other molecules know which cells are invaders and
which belong.
Monoclonal antibody Antibodies that are manufactured specifically to tar-
get cancer cells, by binding to proteins on the cells’ surfaces (Som-
payrac, 2004).
Natural killer cell A type of lymphocyte that is part of both the innate and
adaptive immune system. NK cells can be activated by cytokines or
antibodies, and induce apoptosis in foreign cells.
Partial response A decrease in the size of the tumor in response to treat-
ment (National Cancer Institute, 2010).
Polyp When the cells in the colon are mutated and proliferate too quickly,
they form a mass of cells called a polyp. Only about 1 percent of
polyps become metastatic cancer (Sompayrac, 2004).
Professional phagocyte Leukocytes that are part of the innate immune sys-
tem. These cells engulf invaders.
Proliferate To divide/reproduce/increase in number.
Receptor Proteins on the surface of cells which bind to specific molecules,
usually to send a signal to the cell.
Response rate Percentage of patients whose tumors respond to the treat-
ment (National Cancer Institute, 2010).
T cell Lymphocytes with receptors that each recognize a specific antigen,
which it is their job to find and kill. There are many kinds of T cells,
such as the cytotoxic T cells, which are ready to kill invaders, and the
helper T cells, which are important in directing cells to the invaders.
Upregulation The overproduction of a molecule, such as the upregulation
of growth factor receptors on tumor cells (National Cancer Institute,
2010).

Appendix B
Reference Tables
B.1 Equation Term Descriptions
Equation Term Description
dT
dt aT(1− bT) Logistic tumor growth−cNT NK-induced tumor death
−ξ Ah1+ANT MAB-induced tumor death from NK
cell interactions
−DT CD8+T cell-induced tumor death
−KT(1− e−δTM)T Chemotherapy-induced tumor death
−KATA(1− e−δTM)T MAB-induced tumor death from in-
crease in chemotherapy effectiveness
−ψAT MAB-induced tumor death
dN
dt eC Production of NK cells from circulat-
ing lymphocytes
− f N NK turnover
−pNT NK death by exhaustion of tumor-
killing resources
−pA Ah1+ANT Additional NK death by exhaustion
of tumor-killing resources from MAB
interactions
pNNI
gN+I
Stimulatory effect of IL-2 on NK cells
Continued on next page
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Equation Term Description
−KN(1− e−δNM)N Death of NK cells due to chemother-
apy toxicity
dL
dt
θmL
θ+I CD8
+T-cell turnover
j Tk+T L CD8
+T-cell stimulation by CD8+T
cell-lysed tumor-cell debris
−qLT CD8+T-cell death by exhaustion of
tumor-killing resources
r1NT CD8+T-cell stimulation by NK-lysed
tumor-cell debris
r2CT Activation of natvie CD8+T cells in
the general lymphocyte population
− uL2CIκ+I Breakdown of surplus CD8+T cells in
the presence of IL-2
−KL(1− e−δLM)L Death of CD8+T cells due to
chemotherapy toxicity
pILI
gI+I
Stimulatory effect of IL-2 on CD8+T
cells
dC
dt α Lymphocyte synthesis in bone mar-
row
−βC Lymphocyte turnover
−KC(1− e−δCM)C Death of lymphocytes due to
chemotherapy toxicity
dM
dt −γM Excretion and elimination of
chemotherapy
dI
dt −µI I IL-2 turnover
φC Production of IL-2 due to naive
CD8+T cells and CD4+T cells
ωLI
ζ+I Production of IL-2 from activated
CD8+T cells
dA
dt −ηA Excretion and elimination of MABs
−λT Ah2+A Loss of MABs due to tumor-MAB
binding
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B.2 Parameter Descriptions
Equation Parameter Description
dT
dt a Growth rate of tumor
b Inverse of carrying capacity
c Rate of NK-induced tumor death
ξ Rate of NK-induced tumor death through ADCC
h1 Concentration of MABs for half-maximal increase in
ADCC
KT Rate of chemotherapy-induced tumor death
KAT Additional chemotherapy-induced tumor death due
to MABs
δT Medicine efficacy coefficient
ψ Rate of MAB-induced tumor death
dN
dt
e
f Ratio of NK cell synthesis rate with turnover rate
f Rate of NK cell turnover
p Rate of NK cell death due to tumor interaction
pA Rate of NK cell death due to tumor-MAB complex
interaction
pN Rate of IL-2 induced NK cell proliferation
gN Concentration of IL-2 for half-maximal NK cell pro-
liferation
KN Rate of NK depletion from chemotherapy toxicity
δN Chemotherapy toxicity coefficient
dL
dt m Rate of activated CD8
+T-cell turnover
θ Concentration of IL-2 to halve CD8+T-cell turnover
q Rate of CD8+T-cell death due to tumor interaction
r1 Rate of NK-lysed tumor cell debris activation of
CD8+T cells
r2 Rate of CD8+T-cell production from circulating lym-
phocytes
pI Rate of IL-2 induced CD8+T-cell activation
gI Concentration of IL-2 for half-maximal CD8+T-cell
activation
u CD8+T-cell self-limitation feedback coefficient
Continued on next page
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Equation Parameter Description
κ Concentration of IL-2 to halve magnitude of CD8+T-
cell self-regulation
j Rate of CD8+T-cell lysed tumor cell debris activation
of CD8+ T cells
k Tumor size for half-maximal CD8+T-lysed debris
CD8+T activation
KL Rate of CD8+T-cell depletion from chemotherapy
toxicity
δL Chemotherapy toxicity coefficient
dC
dt
α
β Ratio of rate of circulating lymphocyte production to
turnover rate
β Rate of lymphocyte turnover
KC Rate of lymphocyte depletion from chemotherapy
toxicity
δC Chemotherapy toxicity coefficient
dM
dt γ Rate of excretion and elimination of chemotherapy
drug
dI
dt µI Rate of excretion and elimination of IL-2
ω Rate of IL-2 production from CD8+T cells
φ Rate of IL-2 production from CD4+/naive CD8+T
cells
ζ Concentration of IL-2 for half-maximal CD8+T-cell
IL-2 production
dA
dt η Rate of MAB turnover and excretion
λ Rate of MAB-tumor cell complex formation
h2 Concentration of MABs for half-maximal EGFR
binding
D d Immune-system strength coefficient
l Immune-system strength scaling coefficient
s Value of ( LT )
l necessary for half-maximal CD8+T-cell
toxicity
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B.3 Parameter Values
Equation Parameter Value Units Main Source
dT
dt a 2.31× 10−1 Day−1 Corbett et al. (1975)
b 2.146× 10−10 Cells−1 Leith et al. (1987)
c 5.156× 10−14 L Cells−1Day−1 de Pillis et al. (2009)
ξ 6.5× 10−10∗ L Cells−1Day−1 Kurai et al. (2007)
0∗∗ L Cells−1Day−1 Grothey (2006)
h1 1.25× 10−6∗ mg L−1 Kurai et al. (2007)
0∗∗ mg L−1 Grothey (2006)
KT 0− 8.1× 10−1 Day−1 Vilar et al. (2006)
KAT 4× 10−4∗ L mg−1Day−1 ad hoc value
4× 10−4∗∗ L mg−1Day−1 ad hoc value
δT 2× 10−1 L mg−1 Vilar et al. (2006)
ψ 0− 2.28× 10−2∗ L mg−1Day−1 De Vita, Jr et al. (2000)
0− 2.58× 10−2∗∗ L mg−1Day−1 De Vita, Jr et al. (2000)
dN
dt
e
f
1
9 – de Pillis et al. (2009)
f 1× 10−2 Day−1 Modified from
de Pillis et al. (2009)
p 5.156× 10−14 L Cells−1Day−1 de Pillis et al. (2009)
pA 6.5× 10−10∗ L Cells−1Day−1 Kurai et al. (2007)
0∗∗ L Cells−1Day−1 Grothey (2006)
pN 5.13× 10−2 Day−1 de Pillis et al. (2009)
gN 2.5036× 105 IU L−1 de Pillis et al. (2009)
KN 9.048× 10−1 Day−1 Catimel et al. (1995)
δN 2× 10−1 L mg−1 Vilar et al. (2006)
dL
dt m 5× 10−3 Day−1 Modified from
de Pillis et al. (2009)
θ 2.5036× 10−3 IU L−1 de Pillis et al. (2009)
q 5.156× 10−17 Cells−1Day−1 Modified from
de Pillis et al. (2009)
r1 5.156× 10−12 Cells−1Day−1 de Pillis et al. (2009)
r2 1× 10−15 Cells−1Day−1 Modified from
de Pillis et al. (2009)
pI 2.4036 Day−1 de Pillis et al. (2009)
gI 2.5036× 103 IU L−1 de Pillis et al. (2009)
Continued on next page
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Equation Parameter Value Units Main Source
u 3.1718× 10−14 L2Cells−2Day−1 de Pillis et al. (2009)
κ 2.5036× 103 IU L−1 de Pillis et al. (2009)
j 1.245× 10−4 Day−1 Modified from
de Pillis et al. (2009)
k 2.019× 107 Cells de Pillis et al. (2009)
KL 4.524× 10−1 Day−1 Catimel et al. (1995)
δL 2× 10−1 L mg−1 Vilar et al. (2006)
dC
dt
α
β 3× 109 Cells L−1 InfoNet (2009)
β 6.3× 10−3 Day−1 de Pillis et al. (2009)
KC 5.7× 10−1 Day−1 Catimel et al. (1995)
δC 2× 10−1 L mg−1 Vilar et al. (2006)
dM
dt γ 4.077× 10−1 Day−1 Catimel et al. (1995)
dI
dt µI 11.7427 Day
−1 de Pillis et al. (2009)
ω 7.88× 10−2 IU Cells−1Day−1 de Pillis et al. (2009)
φ 1.788× 10−7 IU Cells−1Day−1 de Pillis et al. (2009)
ζ 2.5036× 103 IU L−1 de Pillis et al. (2009)
dA
dt η 1.386× 10−1∗ Day−1 Grothey (2006)
9.242× 10−2∗∗ Day−1 Grothey (2006)
λ 8.3× 10−14∗ mg Cells−1L−1Day−1 Freeman et al. (2008)
8.6× 10−14∗∗ mg Cells−1L−1Day−1 Freeman et al. (2008)
h2 4.0× 10−5∗ mg L−1 Freeman et al. (2008)
4.05× 10−5∗∗ mg L−1 Freeman et al. (2008)
D d Not Specified Day−1 de Pillis et al. (2009)
l Not Specified – de Pillis et al. (2009)
s Not Specified L−1 de Pillis et al. (2009)
Table B.3: Parameter Values.
∗For cetuximab.
∗∗For panitumumab.
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